Intelligence Platform

Patents

Browse 912 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 9491934

Regulation of endogenous gene expression in cells using zinc finger proteins

Sangamo Biosciences, Inc. · Granted Tue Nov 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9493833

Methods for preventing induced synthesis of proteasomes in human cells

The Regents of the University of California · Granted Tue Nov 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9492538

Isolation and use of solid tumor stem cells

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Nov 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9487753

Compositions of adult disc stem cells and methods for the treatment of degenerative disc d

DiscGenics, Inc. · Granted Tue Nov 08 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9487556

Polyconjugates for delivery of RNAi triggers to tumor cells in vivo

Arrowhead Pharmaceuticals, Inc. · Granted Tue Nov 08 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9481866

Methods of producing T cell populations enriched for stable regulatory T-cells

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Nov 01 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 27 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9474787

Mesenchymal stem cells for the treatment of CNS diseases

BRAINSTORM CELL THERAPEUTICS LTD. · Granted Tue Oct 25 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9468632

Methods and compositions for targeting cancer stem cells

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Oct 18 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 13 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9428731

Technologies, methods, and products of small molecule directed tissue and organ regenerati

San Diego Regenerative Medicine Institute · Granted Tue Aug 30 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9422522

Method of producing adipocytes from fibroblast cells

Regenertech Pty Limited · Granted Tue Aug 23 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9403872

Mutated anthrax toxin protective antigen proteins that specifically target cells containin

The United States of America as Represented by The Secretary of the Department of Health and Human Services National Institutes of Health Office of Technology Transfer · Granted Tue Aug 02 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9404088

Chitosan-based non-viral methods for transfecting gut cells in vivo

ENGENE, INC. · Granted Tue Aug 02 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9371516

Compositions and methods for differentiating stem cells into cell populations comprising b

REGENERATIVE MEDICAL SOLUTIONS, INC. · Granted Tue Jun 21 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 16 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9365823

Virus clearance of neoplastic cells from mixed cellular compositions

ONCOLYTICS BIOTECH INC. · Granted Tue Jun 14 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 09 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9345726

CD117+ cells and uses thereof

The Regents of the University of Colorado, a Body Corporate · Granted Tue May 24 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9333248

Methods and composition related to Th-1 dendritic cells

The Board of Regents of the University of Texas System · Granted Tue May 10 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 05 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9327023

HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue May 03 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9320774

Method for reducing radio-resistance of prostate cancer cells and/or treating prostate can

China Medical University · Granted Tue Apr 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9314486

Preparative regimen for engraftment, growth and differentiation of non-hematopoeitic cells

Montefiore Medical Center · Granted Tue Apr 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9303080

Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells

The United States of America as Represented by The Secretary of the Department of Health and Human Services National Institutes of Health Office of Technology Transfer · Granted Tue Apr 05 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9302015

Anti-PRLR antibodies and methods for killing PRLR-expressing cells

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 05 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9301976

Compositions comprising perivascular stem cells and nell-1 protein

The Regents of the University of California · Granted Tue Apr 05 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9273284

Method for generating potent dendritic cells

The Regents of the University of California · Granted Tue Mar 01 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9243051

Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T-cells

United States Government as represented by the Department of Veterans Affairs · Granted Tue Jan 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted